A Forward Look, The Year Ahead - Research Report on PepsiCo, Inc., The Coca-Cola Company, Covidien plc, Medtronic, Inc. and Monster Beverage Corp

Fri Mar 15, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


NEW YORK,  March 15, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting PepsiCo,
Inc. (NYSE:PEP), The Coca-Cola Company (NYSE:KO), Covidien plc (NYSE: COV),
Medtronic, Inc. (NYSE: MDT) and Monster Beverage Corp (NASDAQ:MNST). Today's
readers may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

PepsiCo, Inc. Research Report

Beating market estimates for the past year, Pepsi reported a 17% increase in the
fourth quarter earnings of  $1.66 billion  or  $1.06  per share, up from the
same year-ago quarter earnings of  $1.42 billion  or  89 cents  per share. The
company also reported an organic revenue growth of 5% for the same quarter and
the full year. With this strong quarter result, Pepsi has announced a new
buyback plan of as much as  $10 billion  in stock to return cash to investors.
This new repurchase program will begin in  July 1, 2013  and will continue until
 June 30, 2013. Furthermore, Pepsi also reported an increase of 5.6% in the
company's annualized dividend for the  June 2013  payment, resulting from  $2.15
 to a price of  $2.27  per share. Pepsi Chairman and CEO  Indra Nooyi  said that
the revenue growth reflects the company's "enviable portfolio of iconic brands."
Nooyi further noted that the company would continue maintaining its hold in the
global market. "Our recent brand-building initiatives and innovation across the
portfolio, including Quaker Real Medleys, Gatorade Energy Chews, Pepsi Next and
Doritos Locos Tacos, are translating into success in the marketplace... We're
encouraged by the progress we're making and expect performance in the coming
year to be consistent with our long-term targets." The Full Research Report on
PepsiCo, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


The Coca-Cola Company Research Report

Meanwhile, Coca Cola's fourth quarter net income was a reported 14% increase or 
$1.87 billion  or  41 cents  per share, up from the  $1.66 billion  of  36 cents
 per share last year. Despite not meeting the estimates, Coca-Cola projected a
strong full-year global volume growth of 4%, while the full-year reported net
revenue growth is 3%. The company also posted remarkable growths in its various
global markets such as  Thailand  (+22%),  India  (+16%) and  Russia  (+8%) for
the full year. Coke Chairman and Chief Executive Officer  Muhtar Kent  said, "We
are pleased with our results we announced today. In a year marked by continued
uncertainty in the global economy, we delivered solid volume, revenue and profit
growth, and we realized further volume and value share gains in nonalcoholic
ready-to-drink beverages." For the coming year, Kent recognizes the necessity of
adapting to the shifts in the global economy. "We must continue investing in our
business so that we get even better -better at collaborating, at innovating, at
listening to consumers, customers and our bottling partners and most
importantly, at executing with precision. All of us at Coca-Cola remain diligent
about our results as we manage our business for continued sustainable long-term
success," he added. The Full Research Report on The Coca-Cola Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Covidien plc Research Report

Irish healthcare company Covidien PLC recently reported first quarter net sales
of  $3.06 billion, with a 5% growth compared to the same year-ago quarter net
sales. Adjusted diluted earnings amounted to  $1.10  per share. In the same
vein, the Medical Devices segment of the company posted a remarkable sales
growth of 8%. "We're off to a very good start in fiscal 2013, with first-quarter
results exceeding our expectations," said Covidien Chairman, President and CEO
José E. Almeida. The Market Devices unit of the company is expected to perform
well and generate "above-market growth." The company has recently received the
FDA approval for its generic CONCERTA extended-release (ER) tablets, a
prescription medication to stimulate the central nervous system. Covidien has
also released the results of its studies validating the efficacy of its
Solitaire FR Thrombectomy for Acute Revascularization (STAR) device. Solitaire
FR is designed to aid patients of acute ischemic stroke by restoring blood flow
and removing blood clots from the vessels. With over 800, 000 patients affected
by acute ischemic stroke every year, Covidien aims to attend to the need of a
solution for this widespread public health issue. "We remain confident that our
robust pipeline of new products, sizable expansion opportunities in emerging
markets and recent promising portfolio additions will enable us to meet the
significant challenges of the global marketplace and to continue to deliver good
operational growth," Almeida said at the conclusion of the quarterly report. The
Full Research Report on Covidien plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge at:


Medtronic, Inc. Research Report

US medical technology company Medtronic Inc.  posted a 4% revenue growth to  $4
billion  or  93 cents  per share. International sales accounted for 46% of the
company's revenue during the said quarter, for a total of  $1.856 billion. Omar
Ishrak, Medtronic Chairman and CEO also conveyed positive outlook brought about
by the company's strong open for 2013 and the latest financial quarter. The
company last week reported the result of a clinical study by The New England
Journal of Medicine on the benefits of Medtronic's deep brain simulation therapy
for Parkinson's disease patients. With an estimated 60,000 American diagnosed
with Parkinson's disease every year, Covidien says that the study's result gives
way to an expansion of beneficial medical management available for patients, as
exemplified through the deep brain simulation. Medtronic also received the FDA
clearance for its AIRvance Bone Screw System that is designed to allow surgeons
to perform hyoid suspension procedure in treating obstructive sleep apnea.
Through aggressive research and development outputs such as AIRvance, Medtronic
is among the leaders in "transforming global healthcare by implementing our
long-term strategies of economic value and globalization." Ishrak further said
that the company remains "committed to delivering dependable growth in a
changing healthcare environment as reflected in our third quarter performance.
Several businesses and regions contributed to our steady growth this quarter,
and we are focused on effectively managing headwinds and tailwinds to deliver
balanced and consistent overall performance." The Full Research Medtronic, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Monster Beverage Corp Research Report

As the maker of the Monster Energy, one of the questioned energy drinks
products, Monster released a statement contesting the agency report and calling
it "highly misleading." The company explained that the DAWN report contains
little to no information about the association between the hospital emergencies
reported and the consumption of energy drinks. Monster also noted that Monster
Energy drinks contain even less caffeine than regular coffeehouse-brewed coffee
and that about 8 billion cans of the energy drinks have been sold and "safely
consumed" in the U.S. and around the world. Currently having a bullish
impression in the community, Monster is set out to roll more new products this
year, along with expansion in the Asian and Central American  market. Addressing
its adrenaline-pumped market, Monster continuously implements its brand
recognition formula by sponsoring extreme sports events, rock concerts and
tours, and affiliations with athletes and personalities. The Full Research
Report on Monster Beverage Corp - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@investors-alliance.com

Main: +1-(480)-745-7826

SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.